New Targets in Next-Generation Treatments for Atopic Dermatitis and Itch

Despite advances in Th2- and JAK/STAT-targeted therapies, many patients with atopic dermatitis (AD) continue to experience residual symptoms, especially pruritus. New approaches are exploring IL-31 inhibition and refined JAK-STAT modulation to address persistent itch, particularly in “clear-skin, persistent-itch” phenotypes. Additional targets include TSLP, IL-1 family cytokines, OX40/OX40L, and Th17/Th22 pathways. Adjunctive device-based modalities—such as phototherapy, transcutaneous electrical nerve stimulation, and cold plasma therapy—are also under investigation. This session will provide an overview of these next-generation therapies.